Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
Is there increased risk from RT in patients with FAP (familial adenomatous polyposis)?
I was only able to find one article with a
small series
Related Questions
How do you manage oxaliplatin-induced splenomegaly?
Would you include the tract in your treatment field in a patient with squamous cell carcinoma of the anal canal presenting with an ano-cutaneous fistula?
How do you counsel patients on imaging findings after liver SBRT for HCC, particularly with regard to expectations on timing to tumor resolution?
How likely is late radiation induced lumbosacral plexopathy from treatment of anal cancer with chemo-RT 20 years ago and how would you manage it?
For a patient with metastatic, poorly differentiated esophageal adenocarcinoma with an excellent systemic response to chemotherapy for 1 year, who now presents with isolated local progression and no new distant disease, would you consider treating the primary site with a higher palliative dose for more durable control?
In a patient with rectal cancer, when would you consider brachytherapy monotherapy or brachytherapy boost after CRT?
In resected intrahepatic cholangiocarcinoma with an R0 margin <1 mm and perineural invasion, would you consider adjuvant RT in addition to capecitabine?
Would you consider SBRT for fibrolamellar HCC that is inoperable?
What are your top takeaways from ASCO GI 2026?
Do you use more stringent liver constraints when treating HCC with SBRT in patients who are CP B8/9 or C?